Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data ...
HerResolve™ first and only assay validated against ground truth of laparoscopy with confirmed histology. Company to Exhibit at Booth #4 BOSTON, MA, UNITED STATES ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple abstracts have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results